Cancer is seen more in older female patients with psoriasis : A cross-sectional study in 1551 patients

Aim: The aim of this study was to establish the potential risk of the development of malignancy in the patients with psoriasis.Material and Methods: A retrospective analysis of psoriasis cases between January 2017 to August 2018 attending the dermatologyclinic at Karabuk Research and Training Hospital was carried out. Patients with psoriasis were screened whether they have anymalignant disease and associated chronic disease including diabetes mellitus and hypertension by using hospital data system.Suspected cases regarding psoriasis or malignant disease were excluded. Findings were compared according to demographiccharacteristics of the patients.Results: A total of 1551 patients with psoriasis was evaluated in the study time. 30 patients (22 women, 8 men) were found to havemalignancy. The most commonly seen malignancy was stomach cancer in women and prostate cancer in men. 2% of patients withpsoriasis had cancer. This rate was 2.5% in female patients and 1% in male patients (p

PDF

___

1. Ogawa E, Sato Y, Minagawa A, et al. Pathogenesis of psoriasis and development of treatment.J Dermatol 2018;45:264-72.
2. Yunusova NV, Kondakova IV, Kolomiets LA, et al. The role of metabolic syndrome variant in the malignant tumors progression. Diabetes Metab Syndr 2018;12:807-12.
3. Gisondi P, Fostini AC, Fossà I, et al. Psoriasis and the metabolic syndrome.Clin Dermatol 2018;36:21-8.
4. Kimball AB, Sundaram M, Cloutier M, et al. ıncreased prevalence of cancer in adult patients with psoriasis in the united states: a claims basedanalysis. J Drugs Dermatol 2018;17:180-6.
5. Rademaker M, Rubel DM, Agnew K, et al. Psoriasis and cancer. An australian/new zealand narrative. Australas J Dermatol 2019;60:12-8.
6. Reddy SP, Martires K, Wu JJ. The risk of melanoma and hematologic cancers in patients with psoriasis. J Am Acad Dermatol. 2017;76:639-47.
7. Chiesa Fuxench ZC, Shin DB, Ogdie Beatty A, et al. The risk of cancer in patients with psoriasis: a population-based cohrt study in the health ımprovement network. JAMA Dermatol 2016;152:282-90.
8. Mendonça FM, de Sousa FR, Barbosa AL, et al. Metabolic syndrome and risk of cancer: which link? Metabolism. 2015;64:182-9.
9. Eheim A, Medrikova D, Herzig S. Immune cells and metabolic dysfunction.Semin Immunopathol 2014;36:13-25.
10. Emre S, Metin A, Demirseren DD, et al. The relationship between oxidative stress, smoking and the clinical severity of psoriasis. J.Eur.Acad.Dermatol.Venereol 2013;27:e370- 75.
11. Reuter S, Gupta SC, Chaturvedi MM, et al. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 2010;49:1603-16.
12. Stern RS; PUVA Follow-Up Study. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study.J Am Acad Dermatol 2012;66:553-62.
13. Pouplard C, Brenaut E, Horreau C, et al. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol 2013;27:36-46.
14. Arellano FM, Wentworth CE, Arana A, et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007;127:808-16.
15. Kobayashi D, Kuriyama N, Hirano K, et al. Malignancy incidences by glycemic control among diabetic patients. Endocr Connect 2018. Dec 1. Pii ec 0355
16. Radišauskas R, Kuzmickienė I, Milinavičienė E, et al. Hypertension, serum lipids and cancer risk: a review of epidemiological evidence. Medicina (Kaunas) 2016;52:89- 98.
17. Cohen AD, Weitzman D, Dreiher J. Psoriasis and hypertension: a case-control study. Acta Derm venereol 2010;90:23-6.
18. White MC, Holman DM, Boehm JE, et al. Age and cancer risk: a potentially modifiable relationship. Am J Prev Med 2014;46:S7-15.
19. International Diabetes Federation. IDF Diabetes Atlas, 6th edition. Brussels, Belgium: International Diabetes Federation, 2013.
20. Arici M, Turgan C, Altun B, et al. Hypertension incidence in Turkey (HinT): a population-based study. J Hypertens 2010;28:240-4.
21. Frentz G, Olsen JH. Malignant tumours and psoriasis: a follow-up study. Br J Dermatol 1999;140:237-42.
22. Egeberg A, Thyssen JP, Gislason GH, et al. Skin cancer in patients with psoriasis. J Eur Acad Dermatol Venereol 2016;30:1349-53.
23. Paradisi A, Didona B, Tabolli S, et al. Reduced frequency of non-melanoma skin cancer in 72,739 patients with psoriasis: a retrospective study. Eur J Dermatol 2017;27:359-62.
24. Prizment AE, Alonso A, Folsom AR, et al. Association between psoriasis and incident cancer: the Iowa’s Women’s Health Study.Cancer Causes Control 2011;22:1003-10.
25. Lee JH, Kim HJ, Han KD, Et al. Cancer risk in 892 089 patients with psoriasis in Korea: a nationwide populationbased cohort study. J Dermatol 2019;46:95-102.
26. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374-403.
27. Dai H, Li WQ, Qureshi AA, et al. Personal history of psoriasis and risk of nonmelanoma skin cancer (NMSC) among women in the United States: a population-based cohort study. J Am Acad Dermatol 2016;75:731-5.